<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02591095</url>
  </required_header>
  <id_info>
    <org_study_id>2015-000193-35</org_study_id>
    <nct_id>NCT02591095</nct_id>
  </id_info>
  <brief_title>A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer</brief_title>
  <acronym>MONAVI-1</acronym>
  <official_title>A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French Cancer Research Hospital Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the progression-free survival (PFS) in the whole cohort of patients with a recurrent platinum-resistant ovarian cancer.</measure>
    <time_frame>the time to progression (or death from any cause) from date of randomization until date of first documented progression or date of death from any cause,whichever came first, assessed up to 12 months. Evaluation at interim and final analyses.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bim expression level</measure>
    <time_frame>biopsy sample before initiation of treatment by ABT-263 and assessment within 6 months after end of inclusions</time_frame>
    <description>Bim expression level expressed by immunohistochemistry on biopsy of relapsing tumor at inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>evaluated every 6 weeks during treatment to progression or death for any cause.(during average 12 months)]</time_frame>
    <description>- Response rate defined by a complete response (CR), a partial response (PR) or a stable disease (SD) according to the RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events according to the NCI CTC AE version 4.0</measure>
    <time_frame>From date of treatment start until end of study participation (during average 12 months)]</time_frame>
    <description>Toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration of ABT-263</measure>
    <time_frame>8-hour post-dose PK on D1 of C1 &amp; 2. Dosage will be done within 12 months after end of inclusions</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual concentration of ABT-263</measure>
    <time_frame>Pre-dose 0 and cycles 3, 4, 6 . Dosage will be done within 12 months after end of inclusions</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Platinum-resistant or Refractory Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>ABT-263</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral Navitoclax (ABT-263) daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <arm_group_label>ABT-263</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Woman older than 18 years

          -  Subjects with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Histologically and/or cytologically documented high grade serous epithelial cancer of
             ovarian, fallopian tube or peritoneum

          -  Platinum resistant ovarian cancer defined as relapsing within 6 months after a
             platinum based chemotherapy OR platinum refractory ovarian cancer defined as
             progressing during a platinum based chemotherapy (excepted refractory patients in
             first line)

          -  Subjects having received at least 2 prior lines of treatments including platinum
             regimen

          -  Subjects who are willing and able to comply with the protocol and study procedures
             including willingness to undergo tumor biopsy before therapy at screening

          -  There is no limitation to prior number of therapies

          -  Patients must have documented disease progression

          -  Subjects who have measurable disease according to Response Evaluation Criteria in
             Solid Tumors (RECIST) v1.1

          -  Adequate bone marrow, renal and hepatic function per local laboratory reference range
             as follows:• Absolute Neutrophil Count ≥ 1500/ mm3

               -  Platelets ≥ 150,000 / mm3

               -  Hemoglobin ≥ 9.0 g/dL

               -  Renal function: Serum creatinine ≤1.2mg/dL or calculated creatinine clearance ≥
                  60mL/min

               -  AST/ALT ≤ 3.0× the upper limit of normal (ULN); [Subjects with liver metastasis
                  may have AST, ALP, and ALT less then or equal to 5.0 X ULN]

               -  Bilirubin ≤ 1.25×ULN

               -  Coagulation: aPTT and PT not to exceed 1.2 × ULN

          -  LVEF &gt; 50% by echocardiograms or MUGA

          -  Patients must give written informed consent

        Exclusion Criteria:

          -  Patient's refusal or impossibility to perform biopsy on relapsing disease

          -  Bowel occlusive syndrome or other gastro-intestinal disorder that does not allow oral
             medication such as malabsorption

          -  Patients with platinum refractory disease in first line

          -  Received radio-immunotherapy within 6 months of 1st dose of study drug

          -  Received steroid therapy for anti-neoplastic intent within 7 days of the 1st dose of
             study drug (Inhaled steroids for asthma, topical steroids, replacement/stress
             corticosteroids, or corticosteroids taken as premedication are allowed)

          -  Consumption of grapefruit or grapefruit products within 3 days prior to the first dose
             of study drug

          -  Patient receiving treatments strong CYP3A4 inhibitors or inducers (Appendix A)

          -  Positive for HIV and VHC

          -  Predisposing condition/currently exhibiting signs of bleeding

          -  Currently receiving anticoagulation therapy, exception of low-dose anticoagulation
             medications for prophylaxis

          -  Received aspirin within 7 days of start dose of study drug

          -  Active peptic ulcer disease / other potentially hemorrhagic esophagitis/gastritis

          -  Active immune thrombocytopenic purpura, autoimmune hemolytic anemia or history of
             being refractory to platelet transfusions (within 1 year of 1st dose of study drug)

          -  Uncontrolled cardiac, renal, neurologic, psychiatric, endocrinologic, metabolic,
             immunologic, or hepatic disease, active systemic fungal infection; diagnosis of fever
             and neutropenia within 1 week of study drug administration

          -  A evidence of current/active malignancies other than ovarian cancer

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICL Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine LACASSAGNE</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

